Browse > Article

A Study on Preparation of 3'-$[^{18}F]$Fluoro-3'-deoxythymidine and Its Biodistribution in 9L Glioma Bearing Rats  

Shim, Ah-Young (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
Moon, Byung-Seok (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
Lee, Tae-Sup (Laboratory of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences)
Lee, Kyo-Chul (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
An, Gwang-Il (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
Yang, Seung-Dae (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
Yu, Kook-Hyun (Department of Chemistry,Dongguk University)
Cheon, Gi-Jeong (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
Choi, Chang-Woon (Laboratory of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences)
Lim, Sang-Moo (Laboratory of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences)
Chun, Kwon-Soo (Laboratory of Radiopharmaceuticals, Korea Institute of Radiological and Medical Sciences)
Publication Information
Nuclear Medicine and Molecular Imaging / v.40, no.5, 2006 , pp. 263-270 More about this Journal
Abstract
Purpose: Several radioisotope-labeled thymidine derivatives such as $[^{11}C]$thymidine was developed to demonstrate cell proliferation in tumor. But it is difficult to track metabolism with $[^{11}C]$thymidine due to rapid in vivo degradation and its short physical half-life. 3'-$[^{18}F]$fluoro-3'-deoxythymidine ($[^{18}F]$FLT) was reported to have the longer half life of fluorine-18 and the lack of metabolic degradation in vivo. Here, we described the synthesis of the 3'-$[^{18}F]$fluoro-3'-deoxythymidine ($[^{18}F]$FLT) and compared with $([^{18}F]FET)\;and\;([^{18}F]FDG)$ in cultured 9L cell and obtained the biodistribution and PET image in 9L tumor hearing rats. Material and Methods: For the synthesis of $[^{18}F]$FLT, 3-N-tert-butoxycarbonyl-(5'-O-(4,4'-dimet hoxytriphenylmethyl)-2'-deoxy-3'-O-(4-nitrobenzenesulfonyl)-${\beta}$-D-threopentofuranosyl)thymine was used as a FLT precursor, on which the tert-butyloxycarbonyl group was introduced to protect N3-position and nitrobenzenesulfonyl group. Radiolabeling of nosyl substitued precursor with $^{18}F$ was performed in acetonitrile at $120^{\circ}C$ and deproteced with 0.5 N HCI. The cell uptake was measured in cultured 9L glioma cell. The biodistribution was evaluated in 9L tumor bearing rats after intravenous injection at 10 min, 30 min, 60 min and 120 min and obtained PET image 60 minutes after injection. Results: The radiochemical yield was about 20-30% and radiochemical purity was more than 95% after HPLC purification. Cellular uptake of $[^{18}F]$FLT was increased as time elapsed. At 120 min post-injection, the ratios of tumor/blood, tumor/muscle and tumor/brain were $1.61{\pm}0.34,\;1.70{\pm}0.30\;and\;9.33{\pm}2.22$, respectively. The 9L tumor was well visualized at 60 min post injection in PET image. Conclusion: The uptake of $[^{18}F]$FLT in tumor was higher than in normal brain and PET image of $[^{18}F]$FLT was acceptable. These results suggest the possibility of $[^{18}F]$FLT at an imaging agent for brain tumor.
Keywords
$[^{18}F]$FLT; PET; brain tumor; tumor imaging;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Eriksson S, Kierdaszuk B, Munch-Peterson B, Oberg B, Johnsson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biophys Res Commun 1991;176: 586-92   DOI   ScienceOn
2 Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, et al.. Comparison of anti-human immunodeficiency virus activities, cellular ransport, and plasma and intracellular pharmacokinatics of 3-fluoro-3-deoxythymidine and 3-azido-3- deoxytbymidine. Antimicrob Agent Chemother Biochem 1992; 36:808-18   DOI   ScienceOn
3 Tjuvajev J, Muraki A, Ginos J, Berk J, Koutcher D, Ballon B. Iododeoxyuridine (IUDR) uptake and retention as a measure of tumor growth. J Nucl Med 1993;34:1152-61
4 Grierson JR, Shields AF. Radiosynthesis of 3-deoxy-3 -[$^{18}F$]fluorothymidine: [$^{18}F$]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000;27:143-56   DOI   ScienceOn
5 Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Henze M, Pritzkow H, et al. A new precursor for the radiosynthesis of [$^{18}F$]FLT. Nucl Med Biol 2002;29:263-73   DOI   ScienceOn
6 Wodarski C, Eisenbarth J, Weber K, Henze M, Haberkorn U, Eisenhut M. Synthesis of 3'-deoxy-3'-[$^{18}F$fluorothymidine with 2,3'-anthydro-5'-O-(4,4'-dimethoxytrityl) thymidine. J Labelled Cpd Radiopharm 2000:43:1211-8   DOI   ScienceOn
7 Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44:2027-32
8 Moon BS, Kim SW, Lee TS, Ahn SH, Lee KC, An GI, et al. Synthesis of O-(3-[$^{18}F$]fluoropropyl)-L-tyrosine (L-[$^{18}F$]FPT) and its biological evaluation in 9L tumor bearing rat. Bull Korean Chem Soc 2005;26:91-6   DOI
9 Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B. Rat studies comparing $^{11}C$-FMAU, $^{18}F$-FLT, and $^{76}Br$-BFU as proliferation markers. J Nucl Med 2002;43:1688-98
10 Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7
11 Mangner TJ, Klecker RW, Anderson L, Shields AF. Synthesis of 2'-deoxy -2'-[$^{18}F$]fluoro-beta-D-arabinofuranosyl nucleosides, [$^{18}F$]FAU, [$^{18}F$]FMAU, [$^{18}F$]FBAU and [$^{18}F$]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [$^{18}F$]labelled FAU, FMAU, FBAU, FlAU. Nucl Med Biol 2003;30:215-24   DOI   ScienceOn
12 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with $^{18}F$-FLT PET: comparison with $^{18}F$-FDG. J Nucl Med 2005;46:945-52
13 Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. 3′-deoxy-3-[$^{18}F$]fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-9   DOI   ScienceOn
14 Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414-9
15 Shields AF, Grierson JR, Dohmen BR, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [$^{18}F$]FLT and positron emission tomography. Nat Med 1998;4:1334-6   DOI   ScienceOn
16 Toyoharaa J, Wakib A, Takamatsub S, Yonekurab Y, Magatac Y, Fujibayashib Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [$^{3}H$]thymidine and [$^{3}H$]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2001;29:281-7
17 Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. 2-[$^{11}C$]thymidine imaging of malignant brain tumors. Cancer Res 1999;59:615-21
18 Martiat P, Ferrant A, Labar D, Cogneau A, Boc C, Michel JL, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgikin's lymphoma using positron emission tomography. J Nucl Med 1998;29:1633-7
19 Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998;39:1757-62
20 Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, et al. Imaging of the brain tumor proliferative activity with [$^{131}I$]iododeoxyuridine. J Nucl Med 1994;35:1407-17